Bli medlem
Bli medlem

Du är här

2016-10-24

Eurocine Vaccines: Eurocine Vaccines announces initiation of clinical study of the nasal influenza vaccine candidate Immunose™ FLU

Eurocine Vaccines today announced the start of a phase I/II clinical
study of the quadrivalent influenza vaccine candidate Immunose™ FLU,
a novel nose drop formulation based on the company's technology
Endocine™ and inactivated split antigens. The first subjects have
been dosed in the study, which is conducted during the present
influenza season, 2016/2017.

"We are very pleased that our nasal influenza vaccine candidate,
Immunose™ FLU, has entered the clinical development stage," said Dr.
Anna-Karin Maltais, Chief Scientific Officer. "This is the first step
on the path to create a better, more effective influenza vaccine for
children."

"After months of preparations, we are at a very exciting point in the
development," said Dr. Marie Olliver, Director of Clinical
Development. "We have been working intensely with our contract
research organizations, and I am particularly satisfied that we have
started the study a bit ahead of schedule".

Dr. Hans Arwidsson, Chief Executive Officer, said "I am impressed by
the commitment and diligence showed by both our internal team and our
team of contract research organizations. This important milestone
will be very valuable to bring to BIO Europe 2016 in Cologne, where I
will have numerous partnering meetings in a couple of weeks' time".

The study is conducted during the present influenza season, 2016/2017,
and the results are expected around mid-2017.

For more information, please contact:

Hans Arwidsson, Ph.D., MBA

CEO of Eurocine Vaccines AB

hans.arwidsson@eurocine-vaccines.com
+46 70 634 0171

About Eurocine Vaccines

Eurocine Vaccines is a publicly listed company, using its clinically
validated technology Endocine™ to develop a patent protected nasal
influenza vaccine for children. Within the market for influenza
vaccines, children is the fastest growing segment. This is due to the
recommendation by the WHO to vaccinate children against influenza.
The company's main project, the nasal quadrivalent influenza vaccine
candidate Immunose™ FLU, is in clinical phase I/II development during
the influenza season 2016/2017 and a report on the study is expected
around mid-2017.

The company plans to license the product to partners for further
development and commercialization.

Eurocine Vaccines, EUCI, is traded at Aktietorget, XSAT.

-----------------------------------------------------------
http://news.cision.com/se/eurocine-vaccines/r/eurocine-vaccines-announce...
http://mb.cision.com/Main/11552/2107540/579270.pdf

Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.